Senti Biosciences, Inc. Common Stock
SNTISenti Biosciences, Inc. is a biotechnology company focused on developing programmable cell therapies using synthetic biology. The company's platform integrates genetic engineering and computational design to create advanced cell-based medicines aimed at treating diseases such as cancer, autoimmune disorders, and rare genetic conditions.
Company News
Over 100 pharmaceutical companies are actively developing 150+ pipeline drugs for Acute Myeloid Leukemia (AML), with approximately 10 drugs in late-stage development and 50+ in mid and early stages, focusing on targeted therapies and personalized treatment approaches.
Amerant Bancorp Inc. (AMTB) reported Q1 2025 earnings that missed consensus estimates, causing its stock price to drop 13.09%. Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by the company and its officers/directors.
Senti Biosciences, Inc. (SNTI) has stopped enrollment in a clinical trial for its solid tumor pipeline product SN301A due to observed dose-limiting toxicities, causing a 27.2% drop in the company's stock price.
Senti Biosciences, a clinical-stage biotechnology company, announced that it will present positive preliminary clinical results of its lead program SENTI-202 in the treatment of patients with Relapsed/Refractory AML on May 8, 2025.
The NK cell therapy market is experiencing significant growth, driven by rising interest in immuno-oncology and advancements in cell engineering technologies. Key players are investing in innovative approaches, including combination therapies and gene-modified NK cells, to improve clinical outcomes.
